Table 1 Characteristics of patients at time of histoplasmosis diagnosis. Information was collected on patient demographics and IM prior to histoplasmosis diagnosis
Patient | Age (yr) at Histoplasmosis Diagnosis, Sex | Rheumatic Disease | Anti-TNFa (duration of Therapy in Months Prior to Histoplasmosis Diagnosis) | Other Pre-histoplasmosis IM (month duration) |
|---|---|---|---|---|
1 | 11, F | JIA, Psoriatic | Adalimumab (0.5) | MTX (5) |
2 | 17, F | JIA, Poly | Etanercept (1.3) | MTX (7), burst steroids (1) |
3 | 18, F | JIA, Psoriatic | Infliximab (14.1) | MTX (23) |
4 | 15, F | cSLE | - | MTX (3), HCQ (5), burst steroids (12.8) |
5 | 16, F | JIA, Enthesitis | - | None |
6 | 9, M | JIA, Enthesitis | Adalimumab (1.3) | MTX (15) |
7 | 17, F | JIA, Oligo | - | MTX (18) |
8 | 16, M | MCTD | - | MTX (31), HCQ (32), maintenance steroids (30) |
9 | 5, F | JIA, Poly | - | None |
Summary, % or Median (range): | 16 [5,6,7,8,9,10,11,12,13,14,15,16,17,18], 78 % F | 7 JIA, 1 cSLE, 1 MCTD | 44 % TNFai, 1.3 (0.5–14.1) | 78 % DMARD, 18 (4.6–32) 33 % Steroids, 13 (0.6–30) |